Neovasc Completes $2 Million Non-Brokered Private...(s for the rapidly growing vascular and s...),Health

Date:4/24/2009

s for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer(TM), a novel stent in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and as key components in a variety of third party medical products. For more information, visit: www.neovasc.com.

About Frost Group, LLC

The Frost Group, LLC, is a private investment firm based in Miami. The Frost Group is led by Dr. Phillip Frost, and includes Jane Hsiao, Ph.D., Rao Uppaluri, Ph.D., and Steven D. Rubin, a team that has been together in various capacities for over 22 years. Since its formation in October 2006, the Frost Group has invested over $140 million in various companies and technologies in the United States and abroad. These investments include stakes in the areas of pharmaceuticals, diagnostic devices, medical devices, developmental education and entertainment for children, telecommunications, sports licensing, aviation services, software for seismic data analysis, and new materials for computer chips.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Neovasc Inc. Reports Year 2008 Financial Results
2. Neovasc to Raise $2 Million in Non-Brokered Private Placement
3. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
4. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
5. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
6. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
7. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
8. Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank
9. Pharmos Completes Private Placement - Raises $1.8 Million
10. Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
11. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders